Information  X 
Enter a valid email address

Checkit PLC (CKT)

  Print   

Tuesday 01 February, 2022

Checkit PLC

Contract win

RNS Number : 2252A
Checkit PLC
01 February 2022
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION   596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN.

 

1 February 2022

 

Checkit plc

 

("Checkit" or the "Group")

 

Contract win

 

Checkit plc (AIM: CKT) is pleased to announce it has signed a three year contract with Biomat USA, Inc., a subsidiary of Grifols S.A. ("Grifols"). The contract has a minimum total value of £2.8 million spread evenly over the three year period, and will involve providing services to over 300 sites which will see Checkit extend its US footprint within Grifols to initially five of its US subsidiaries.

 

Grifols is a global leader in the production of plasma-derived medicine and transfusion medicines. Headquartered in Spain, it has a worldwide network of over 350 plasma centres, including more than 50 in Europe. With revenues of €5.3bn (of which €3.6bn were generated from US operations during 2020), Grifols employs 24,000 people providing products and services in more than 100 countries worldwide.

 

Of the total contract value, approximately 12% represents the renewal of existing business with Grifols with the remainder representing upsell and new business.

 

The agreement establishes Checkit as Grifols' partner of choice for the provision of intelligent operations technology in the US. In addition, expansion of the Checkit platform to cover Grifols' key countries of operations in Europe is at advanced stages of discussion.

 

Additionally, Grifols plans to build 20 plasma centres in Egypt, with Checkit having recently signed a separate three year contract to provide intelligent operations services to the first ten of these.

 

Checkit CEO Kit Kyte said: "We look forward to the continued growth of our relationship internationally. Our partners at Grifols already appreciate the power of our monitoring services and the future addition of workflow management will give them unprecedented levels of digital control and data-driven insight, as we look for ways to streamline their complex, globally distributed operations. This deal provides further confirmation of the importance of our technology in enabling intelligent operations across deskless workforces."

 

 

Enquiries:

Checkit plc

 

+44 (0)1223 643313

www.checkit.net

 

 

Kit Kyte (Chief Executive Officer)

 

 

Greg Price (Chief Financial Officer)

 

 

 

 

 

Singer Capital Markets (Nominated Adviser & Broker)

 

+44 (0) 20 7496 3000

Shaun Dobson / Harry Gooden / George Tzimas (Investment Banking)

 

 

 

 

About Checkit

 

Checkit is the intelligent operations platform for deskless workforces, enabling operational agility and intelligent decision-making in large multinational and complex national organisations. The solution offers optional plugins for sensor networks and smart building management.

 

The Checkit Connect platform prompts, guides, captures and analyses frontline activities through digital workflows. Real-time data is captured from multiple workplaces. The platform empowers leaders to comprehend and continually improve processes, enhancing innovation, productivity, efficiency, energy usage, waste reduction, customer experience, safety and compliance.

 

Checkit provides intelligent operations tools to the retail, franchise, healthcare, life sciences, facilities management, catering, manufacturing, hospitality and commercial property sectors.

 

Checkit has customers including the UK NHS, bp, Waitrose, Sodexo and Center Parcs. The Checkit platform generates around 11bn data points per year from sensors and digital workflows.

 

Checkit is headquartered in Cambridge, UK, with its operations centre in Fleet, UK, and US office in Florida. The company has over 185 employees.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTFLFSTLLILVIF

a d v e r t i s e m e n t